Compare Nexgen Energy Ltd. Common Shares (NXE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nexgen Energy Ltd. Common Shares vs Organon & Co. Common Stock — how do they compare? Nexgen Energy Ltd. Common Shares trades at $8.1 (market cap $5.67B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Nexgen Energy Ltd. Common Shares is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Nexgen Energy Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nexgen Energy Ltd. Common Shares for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| NXE | OGN | |
|---|---|---|
Market Cap | $5.67B | $3.62B |
Volume | 4,335,942 | 2,892,999 |
Sector | Energy | Health |
52-Week High | $13.92 | $13.81 |
52-Week Low | $7.56 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.42B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NexGen Energy (NXE) trades at $8.47, down 1.28% today, with a bearish technical signal from moving averages despite neutral oscillators. The company shows no current revenue but is advancing its Rook I uranium project targeting first production in 2030. Recent news highlights institutional buying and positive analyst sentiment amid expectations of long-term uranium supply deficits. Financials reflect pre-revenue development stage with negative profitability metrics and significant cash burn.
NXE presents a high-risk, high-potential opportunity as a pure-play uranium developer with strong analyst support but substantial execution risk. The bullish uranium market thesis contrasts with current financial losses and project development timelines. Investment appeal hinges on successful project financing and uranium price sustainability, with near-term volatility expected during construction phase.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
